-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Nimodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group
Category:
TIME：2025-03-19
On March 19, the nimodipine active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for registration by the National Medical Products Administration and officially listed as an API used in marketed dosage forms. This marks another “dihydropyridine” class antihypertensive API to receive approval, following the 2025 approvals for benidipine hydrochloride and nicardipine hydrochloride APIs.
To date, the Group has cumulatively obtained approval for 71 bulk and specialty API varieties, with Guangxiang Pharmaceutical securing approval for 40 new API products.
According to available information, nimodipine is a second-generation dihydropyridine calcium channel blocker, primarily indicated for the treatment of ischemic cerebrovascular diseases, migraine, sudden sensorineural hearing loss, mild to moderate hypertension, and the prevention of cerebral vasospasm following mild subarachnoid hemorrhage, as well as for the management of age-related cognitive impairment.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
